Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 342

1.

Environmental Exposures during Puberty: Window of Breast Cancer Risk and Epigenetic Damage.

Natarajan R, Aljaber D, Au D, Thai C, Sanchez A, Nunez A, Resto C, Chavez T, Jankowska MM, Benmarhnia T, Yang JA, Jones V, Tomsic J, McCune JS, Sistrunk C, Doan S, Serrano M, Cardiff RD, Dietze EC, Seewaldt VL.

Int J Environ Res Public Health. 2020 Jan 13;17(2). pii: E493. doi: 10.3390/ijerph17020493. Review.

2.

The atypical cyclin-like protein Spy1 overrides p53-mediated tumour suppression and promotes susceptibility to breast tumourigenesis.

Fifield BA, Qemo I, Kirou E, Cardiff RD, Porter LA.

Breast Cancer Res. 2019 Dec 11;21(1):140. doi: 10.1186/s13058-019-1211-3.

3.

A cancer rainbow mouse for visualizing the functional genomics of oncogenic clonal expansion.

Boone PG, Rochelle LK, Ginzel JD, Lubkov V, Roberts WL, Nicholls PJ, Bock C, Flowers ML, von Furstenberg RJ, Stripp BR, Agarwal P, Borowsky AD, Cardiff RD, Barak LS, Caron MG, Lyerly HK, Snyder JC.

Nat Commun. 2019 Dec 2;10(1):5490. doi: 10.1038/s41467-019-13330-y.

4.

The comprehensive role of E-cadherin in maintaining prostatic epithelial integrity during oncogenic transformation and tumor progression.

Olson A, Le V, Aldahl J, Yu EJ, Hooker E, He Y, Lee DH, Kim WK, Cardiff RD, Geradts J, Sun Z.

PLoS Genet. 2019 Oct 28;15(10):e1008451. doi: 10.1371/journal.pgen.1008451. eCollection 2019 Oct.

5.

Loss of the tumor suppressor, Tp53, enhances the androgen receptor-mediated oncogenic transformation and tumor development in the mouse prostate.

He Y, Johnson DT, Yang JS, Wu H, You S, Yoon J, Lee DH, Kim WK, Aldahl J, Le V, Hooker E, Yu EJ, Geradts J, Cardiff RD, Sun Z.

Oncogene. 2019 Sep;38(38):6507-6520. doi: 10.1038/s41388-019-0901-8. Epub 2019 Jul 29.

6.

Deletion of the p16INK4a tumor suppressor and expression of the androgen receptor induce sarcomatoid carcinomas with signet ring cells in the mouse prostate.

Lee DH, Yu EJ, Aldahl J, Yang J, He Y, Hooker E, Le V, Mi J, Olson A, Wu H, Geradts J, Xiao GQ, Gonzalgo ML, Cardiff RD, Sun Z.

PLoS One. 2019 Jan 24;14(1):e0211153. doi: 10.1371/journal.pone.0211153. eCollection 2019.

7.

The WNT10B Network Is Associated with Survival and Metastases in Chemoresistant Triple-Negative Breast Cancer.

El Ayachi I, Fatima I, Wend P, Alva-Ornelas JA, Runke S, Kuenzinger WL, Silva J, Silva W, Gray JK, Lehr S, Barch HC, Krutilina RI, White AC, Cardiff R, Yee LD, Yang L, O'Regan RM, Lowry WE, Seagroves TN, Seewaldt V, Krum SA, Miranda-Carboni GA.

Cancer Res. 2019 Mar 1;79(5):982-993. doi: 10.1158/0008-5472.CAN-18-1069. Epub 2018 Dec 18.

8.

Digital Microscopy, Image Analysis, and Virtual Slide Repository.

Aeffner F, Adissu HA, Boyle MC, Cardiff RD, Hagendorn E, Hoenerhoff MJ, Klopfleisch R, Newbigging S, Schaudien D, Turner O, Wilson K.

ILAR J. 2018 Dec 1;59(1):66-79. doi: 10.1093/ilar/ily007.

9.

A Review of Current Standards and the Evolution of Histopathology Nomenclature for Laboratory Animals.

Elmore SA, Cardiff R, Cesta MF, Gkoutos GV, Hoehndorf R, Keenan CM, McKerlie C, Schofield PN, Sundberg JP, Ward JM.

ILAR J. 2018 Dec 1;59(1):29-39. doi: 10.1093/ilar/ily005.

10.

Chronic expression of wild-type Ret receptor in the mammary gland induces luminal tumors that are sensitive to Ret inhibition.

Gattelli A, García Solá ME, Roloff TC, Cardiff RD, Kordon EC, Chodosh LA, Hynes NE.

Oncogene. 2018 Jul;37(29):4046-4054. doi: 10.1038/s41388-018-0235-y. Epub 2018 Apr 26.

PMID:
29695833
11.

Aging Mouse Models Reveal Complex Tumor-Microenvironment Interactions in Cancer Progression.

Mori H, Cardiff RD, Borowsky AD.

Front Cell Dev Biol. 2018 Mar 29;6:35. doi: 10.3389/fcell.2018.00035. eCollection 2018. Review.

12.

Promotion of tobacco products on Facebook: policy versus practice.

Jackler RK, Li VY, Cardiff RAL, Ramamurthi D.

Tob Control. 2019 Jan;28(1):67-73. doi: 10.1136/tobaccocontrol-2017-054175. Epub 2018 Apr 5.

PMID:
29622602
13.

Pathobiology of the 129:Stat1 -/- mouse model of human age-related ER-positive breast cancer with an immune infiltrate-excluded phenotype.

Mori H, Chen JQ, Cardiff RD, Pénzváltó Z, Hubbard NE, Schuetter L, Hovey RC, Trott JF, Borowsky AD.

Breast Cancer Res. 2017 Sep 2;19(1):102. doi: 10.1186/s13058-017-0892-8.

14.

β-Catenin haploinsufficiency promotes mammary tumorigenesis in an ErbB2-positive basal breast cancer model.

Bui T, Schade B, Cardiff RD, Aina OH, Sanguin-Gendreau V, Muller WJ.

Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):E707-E716. doi: 10.1073/pnas.1610383114. Epub 2017 Jan 17. Erratum in: Proc Natl Acad Sci U S A. 2017 Mar 14;114(11):E2265. Tung, Bui [corrected to Bui, Tung].

15.

Methods of Immunohistochemistry and Immunofluorescence: Converting Invisible to Visible.

Mori H, Cardiff RD.

Methods Mol Biol. 2016;1458:1-12. doi: 10.1007/978-1-4939-3801-8_1.

PMID:
27581010
16.

Decoding Intratumoral Heterogeneity of Breast Cancer by Multiparametric In Vivo Imaging: A Translational Study.

Schmitz J, Schwab J, Schwenck J, Chen Q, Quintanilla-Martinez L, Hahn M, Wietek B, Schwenzer N, Staebler A, Kohlhofer U, Aina OH, Hubbard NE, Reischl G, Borowsky AD, Brucker S, Nikolaou K, la Fougère C, Cardiff RD, Pichler BJ, Schmid AM.

Cancer Res. 2016 Sep 15;76(18):5512-22. doi: 10.1158/0008-5472.CAN-15-0642. Epub 2016 Jul 27.

17.

The ErbB2ΔEx16 splice variant is a major oncogenic driver in breast cancer that promotes a pro-metastatic tumor microenvironment.

Turpin J, Ling C, Crosby EJ, Hartman ZC, Simond AM, Chodosh LA, Rennhack JP, Andrechek ER, Ozcelik J, Hallett M, Mills GB, Cardiff RD, Gray JW, Griffith OL, Muller WJ.

Oncogene. 2016 Nov 24;35(47):6053-6064. doi: 10.1038/onc.2016.129. Epub 2016 May 9.

18.

Multipotent luminal mammary cancer stem cells model tumor heterogeneity.

Bao L, Cardiff RD, Steinbach P, Messer KS, Ellies LG.

Breast Cancer Res. 2015 Oct 14;17(1):137. doi: 10.1186/s13058-015-0615-y.

19.

"Score the Core" Web-based pathologist training tool improves the accuracy of breast cancer IHC4 scoring.

Engelberg JA, Retallack H, Balassanian R, Dowsett M, Zabaglo L, Ram AA, Apple SK, Bishop JW, Borowsky AD, Carpenter PM, Chen YY, Datnow B, Elson S, Hasteh F, Lin F, Moatamed NA, Zhang Y, Cardiff RD.

Hum Pathol. 2015 Nov;46(11):1694-704. doi: 10.1016/j.humpath.2015.07.008. Epub 2015 Jul 29.

PMID:
26410019
20.

The Trp53 delta proline (Trp53ΔP) mouse exhibits increased genome instability and susceptibility to radiation-induced, but not spontaneous, tumor development.

Adams CJ, Yu JS, Mao JH, Jen KY, Costes SV, Wade M, Shoemake J, Aina OH, Del Rosario R, Menchavez PT, Cardiff RD, Wahl GM, Balmain A.

Mol Carcinog. 2016 Sep;55(9):1387-96. doi: 10.1002/mc.22377. Epub 2015 Aug 27.

21.

PIK3CA(H1047R) induces multipotency and multi-lineage mammary tumours.

Koren S, Reavie L, Couto JP, De Silva D, Stadler MB, Roloff T, Britschgi A, Eichlisberger T, Kohler H, Aina O, Cardiff RD, Bentires-Alj M.

Nature. 2015 Sep 3;525(7567):114-8. doi: 10.1038/nature14669. Epub 2015 Aug 12.

PMID:
26266975
22.

Neoplastic transformation of porcine mammary epithelial cells in vitro and tumor formation in vivo.

Rowson-Hodel AR, Manjarin R, Trott JF, Cardiff RD, Borowsky AD, Hovey RC.

BMC Cancer. 2015 Jul 31;15:562. doi: 10.1186/s12885-015-1572-7.

23.

Introduction of Zinc-salt Fixation for Effective Detection of Immune Cell-related Markers by Immunohistochemistry.

Mori H, Soonsawad P, Schuetter L, Chen Q, Hubbard NE, Cardiff RD, Borowsky AD.

Toxicol Pathol. 2015 Aug;43(6):883-9. doi: 10.1177/0192623315587593. Epub 2015 Jul 7.

24.

Abnormal Mammary Development in 129:STAT1-Null Mice is Stroma-Dependent.

Chen JQ, Mori H, Cardiff RD, Trott JF, Hovey RC, Hubbard NE, Engelberg JA, Tepper CG, Willis BJ, Khan IH, Ravindran RK, Chan SR, Schreiber RD, Borowsky AD.

PLoS One. 2015 Jun 15;10(6):e0129895. doi: 10.1371/journal.pone.0129895. eCollection 2015.

25.

Kinase-independent role of cyclin D1 in chromosomal instability and mammary tumorigenesis.

Casimiro MC, Di Sante G, Crosariol M, Loro E, Dampier W, Ertel A, Yu Z, Saria EA, Papanikolaou A, Li Z, Wang C, Addya S, Lisanti MP, Fortina P, Cardiff RD, Tozeren A, Knudsen ES, Arnold A, Pestell RG.

Oncotarget. 2015 Apr 20;6(11):8525-38.

26.

Magnetic resonance imaging assessment of effective ablated volume following high intensity focused ultrasound.

Fite BZ, Wong A, Liu Y, Mahakian LM, Tam SM, Aina O, Hubbard NE, Borowsky A, Cardiff RD, Dumont E, Ferrara KW.

PLoS One. 2015 Mar 18;10(3):e0120037. doi: 10.1371/journal.pone.0120037. eCollection 2015.

27.

Regulation of glutamine carrier proteins by RNF5 determines breast cancer response to ER stress-inducing chemotherapies.

Jeon YJ, Khelifa S, Ratnikov B, Scott DA, Feng Y, Parisi F, Ruller C, Lau E, Kim H, Brill LM, Jiang T, Rimm DL, Cardiff RD, Mills GB, Smith JW, Osterman AL, Kluger Y, Ronai ZA.

Cancer Cell. 2015 Mar 9;27(3):354-69. doi: 10.1016/j.ccell.2015.02.006.

28.

Mice deficient in Rbm38, a target of the p53 family, are susceptible to accelerated aging and spontaneous tumors.

Zhang J, Xu E, Ren C, Yan W, Zhang M, Chen M, Cardiff RD, Imai DM, Wisner E, Chen X.

Proc Natl Acad Sci U S A. 2014 Dec 30;111(52):18637-42. doi: 10.1073/pnas.1415607112. Epub 2014 Dec 15.

29.

TMPRSS2:ERG blocks neuroendocrine and luminal cell differentiation to maintain prostate cancer proliferation.

Mounir Z, Lin F, Lin VG, Korn JM, Yu Y, Valdez R, Aina OH, Buchwalter G, Jaffe AB, Korpal M, Zhu P, Brown M, Cardiff RD, Rocnik JL, Yang Y, Pagliarini R.

Oncogene. 2015 Jul;34(29):3815-25. doi: 10.1038/onc.2014.308. Epub 2014 Sep 29.

PMID:
25263440
30.

The E2F transcription factors regulate tumor development and metastasis in a mouse model of metastatic breast cancer.

Hollern DP, Honeysett J, Cardiff RD, Andrechek ER.

Mol Cell Biol. 2014 Sep;34(17):3229-43. doi: 10.1128/MCB.00737-14. Epub 2014 Jun 16.

31.

Analysis of mouse model pathology: a primer for studying the anatomic pathology of genetically engineered mice.

Cardiff RD, Miller CH, Munn RJ.

Cold Spring Harb Protoc. 2014 Jun 2;2014(6):561-80. doi: 10.1101/pdb.top069922.

PMID:
24890215
32.

Manual immunohistochemistry staining of mouse tissues using the avidin-biotin complex (ABC) technique.

Cardiff RD, Miller CH, Munn RJ.

Cold Spring Harb Protoc. 2014 Jun 2;2014(6):659-62. doi: 10.1101/pdb.prot073429.

PMID:
24890206
33.

Manual hematoxylin and eosin staining of mouse tissue sections.

Cardiff RD, Miller CH, Munn RJ.

Cold Spring Harb Protoc. 2014 Jun 2;2014(6):655-8. doi: 10.1101/pdb.prot073411.

PMID:
24890205
34.

Mouse tissue fixation.

Cardiff RD, Miller CH, Munn RJ.

Cold Spring Harb Protoc. 2014 May 1;2014(5). pii: pdb.prot073403. doi: 10.1101/pdb.prot073403.

PMID:
24786501
35.

Limited mouse necropsy.

Cardiff RD, Miller CH, Munn RJ.

Cold Spring Harb Protoc. 2014 May 1;2014(5). pii: pdb.prot073395. doi: 10.1101/pdb.prot073395.

PMID:
24786500
36.

The use of mouse models of breast cancer and quantitative image analysis to evaluate hormone receptor antigenicity after microwave-assisted formalin fixation.

Engelberg JA, Giberson RT, Young LJ, Hubbard NE, Cardiff RD.

J Histochem Cytochem. 2014 May;62(5):319-34. doi: 10.1369/0022155414529250. Epub 2014 Mar 28.

37.

Mislocalization of the cell polarity protein scribble promotes mammary tumorigenesis and is associated with basal breast cancer.

Feigin ME, Akshinthala SD, Araki K, Rosenberg AZ, Muthuswamy LB, Martin B, Lehmann BD, Berman HK, Pietenpol JA, Cardiff RD, Muthuswamy SK.

Cancer Res. 2014 Jun 1;74(11):3180-94. doi: 10.1158/0008-5472.CAN-13-3415. Epub 2014 Mar 24.

38.

At last: classification of human mammary cells elucidates breast cancer origins.

Cardiff RD, Borowsky AD.

J Clin Invest. 2014 Feb;124(2):478-80. doi: 10.1172/JCI73910. Epub 2014 Jan 27.

39.

Accumulation, internalization and therapeutic efficacy of neuropilin-1-targeted liposomes.

Paoli EE, Ingham ES, Zhang H, Mahakian LM, Fite BZ, Gagnon MK, Tam S, Kheirolomoom A, Cardiff RD, Ferrara KW.

J Control Release. 2014 Mar 28;178:108-17. doi: 10.1016/j.jconrel.2014.01.005. Epub 2014 Jan 13.

40.

Contribution of an alveolar cell of origin to the high-grade malignant phenotype of pregnancy-associated breast cancer.

Haricharan S, Hein SM, Dong J, Toneff MJ, Aina OH, Rao PH, Cardiff RD, Li Y.

Oncogene. 2014 Dec 11;33(50):5729-39. doi: 10.1038/onc.2013.521. Epub 2013 Dec 9.

41.

Structured reporting in anatomic pathology for coclinical trials: the caELMIR model.

Cardiff RD, Miller CH, Munn RJ, Galvez JJ.

Cold Spring Harb Protoc. 2014 Jan 1;2014(1):32-43. doi: 10.1101/pdb.top078790.

PMID:
24173313
42.

Expression of PIK3CA mutant E545K in the mammary gland induces heterogeneous tumors but is less potent than mutant H1047R.

Meyer DS, Koren S, Leroy C, Brinkhaus H, Müller U, Klebba I, Müller M, Cardiff RD, Bentires-Alj M.

Oncogenesis. 2013 Sep 30;2:e74. doi: 10.1038/oncsis.2013.38.

43.

ETV4 promotes metastasis in response to activation of PI3-kinase and Ras signaling in a mouse model of advanced prostate cancer.

Aytes A, Mitrofanova A, Kinkade CW, Lefebvre C, Lei M, Phelan V, LeKaye HC, Koutcher JA, Cardiff RD, Califano A, Shen MM, Abate-Shen C.

Proc Natl Acad Sci U S A. 2013 Sep 10;110(37):E3506-15. doi: 10.1073/pnas.1303558110. Epub 2013 Aug 5.

44.

An integrin binding-defective mutant of insulin-like growth factor-1 (R36E/R37E IGF1) acts as a dominant-negative antagonist of the IGF1 receptor (IGF1R) and suppresses tumorigenesis but still binds to IGF1R.

Fujita M, Ieguchi K, Cedano-Prieto DM, Fong A, Wilkerson C, Chen JQ, Wu M, Lo SH, Cheung AT, Wilson MD, Cardiff RD, Borowsky AD, Takada YK, Takada Y.

J Biol Chem. 2013 Jul 5;288(27):19593-603. doi: 10.1074/jbc.M113.470872. Epub 2013 May 21.

45.

Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee.

Ittmann M, Huang J, Radaelli E, Martin P, Signoretti S, Sullivan R, Simons BW, Ward JM, Robinson BD, Chu GC, Loda M, Thomas G, Borowsky A, Cardiff RD.

Cancer Res. 2013 May 1;73(9):2718-36. doi: 10.1158/0008-5472.CAN-12-4213. Epub 2013 Apr 22.

46.

Single unpurified breast tumor-initiating cells from multiple mouse models efficiently elicit tumors in immune-competent hosts.

Kurpios NA, Girgis-Gabardo A, Hallett RM, Rogers S, Gludish DW, Kockeritz L, Woodgett J, Cardiff R, Hassell JA.

PLoS One. 2013;8(3):e58151. doi: 10.1371/journal.pone.0058151. Epub 2013 Mar 26.

47.

Met synergizes with p53 loss to induce mammary tumors that possess features of claudin-low breast cancer.

Knight JF, Lesurf R, Zhao H, Pinnaduwage D, Davis RR, Saleh SM, Zuo D, Naujokas MA, Chughtai N, Herschkowitz JI, Prat A, Mulligan AM, Muller WJ, Cardiff RD, Gregg JP, Andrulis IL, Hallett MT, Park M.

Proc Natl Acad Sci U S A. 2013 Apr 2;110(14):E1301-10. doi: 10.1073/pnas.1210353110. Epub 2013 Mar 18.

48.

Lineage analysis of basal epithelial cells reveals their unexpected plasticity and supports a cell-of-origin model for prostate cancer heterogeneity.

Wang ZA, Mitrofanova A, Bergren SK, Abate-Shen C, Cardiff RD, Califano A, Shen MM.

Nat Cell Biol. 2013 Mar;15(3):274-83. doi: 10.1038/ncb2697. Epub 2013 Feb 24.

49.

Quantitation of fixative-induced morphologic and antigenic variation in mouse and human breast cancers.

Cardiff RD, Hubbard NE, Engelberg JA, Munn RJ, Miller CH, Walls JE, Chen JQ, Velásquez-García HA, Galvez JJ, Bell KJ, Beckett LA, Li YJ, Borowsky AD.

Lab Invest. 2013 Apr;93(4):480-97. doi: 10.1038/labinvest.2013.10. Epub 2013 Feb 11.

50.

ATG proteins mediate efferocytosis and suppress inflammation in mammary involution.

Teplova I, Lozy F, Price S, Singh S, Barnard N, Cardiff RD, Birge RB, Karantza V.

Autophagy. 2013 Apr;9(4):459-75. doi: 10.4161/auto.23164. Epub 2013 Feb 4.

Supplemental Content

Loading ...
Support Center